𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient

✍ Scribed by D. Neau; E. Schvoerer; D. Robert; F. Dubois; H. Dutronc; H.J.A. Fleury; J.M. Ragnaud


Book ID
111722523
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
53 KB
Volume
41
Category
Article
ISSN
0163-4453

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Efficacy of lamivudine in patients with
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Long-term incidence of hepatitis B virus
✍ Yves Benhamou; Marie Bochet; Vincent Thibault; Vincent Di Martino; Eric Caumes; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Hepatitis B virus (HBV) resistance to lamivudine has not been extensively documented in human immunodeficiency virus (HIV)-infected patients. We studied the long-term incidence of HBV resistance to lamivudine in HIV-positive patients. Sixty-six HIV-HBV-coinfected patients were studied while receivin